About Us

In the global oncology market, cell therapy is widely recognized as one of the most transformative approaches.
However, it has yet to scale into a true global industry due to three core limitations:
lack of standardization, limited manufacturing capacity, and extremely high costs.

If we look at one of the most successful global industries—semiconductors—
their success was not driven by technology alone,
but by standardized processes, mass production, and global scalability.

​

SL BIO’s GDT platform is the first to truly bring this industrial logic into cell therapy.
It transforms cell therapy from a highly customized medical procedure
into a platform-based, modular, scalable, and reproducible business model.

We believe GDT is not just a new therapy—it is a global cell therapy platform.
Its opportunity extends beyond oncology, into the future of immune-based medicine worldwide.